C Swanson1,2, S A Shea3,4,5, P Wolfe6, S Markwardt5, S W Cain4,7,8, M Munch9, C A Czeisler4,7, E S Orwoll10, O M Buxton4,7,11,12. 1. Division of Endocrinology and Bone and Mineral Unit, Oregon Health & Science University, Portland, OR, USA. Christine.Swanson@UCDenver.edu. 2. Division of Endocrinology, University of Colorado, 12801 E. 17th Ave. Mail Stop 8106, Aurora, CO, 80045, USA. Christine.Swanson@UCDenver.edu. 3. Oregon Institute of Occupational Health Sciences, Oregon Health & Science University, Portland, OR, USA. 4. Sleep Health Institute, Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital, Boston, MA, USA. 5. OHSU-PSU School of Public Health, Portland, OR, USA. 6. Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 7. Division of Sleep Medicine, Harvard Medical School, Boston, MA, USA. 8. Monash Institute of Cognitive and Clinical Neurosciences, School of Psychological Sciences, Monash University, Clayton, VIC, 3800, Australia. 9. Charité University Medicine Berlin, Institute of Physiology, Berlin, Germany. 10. Division of Endocrinology and Bone and Mineral Unit, Oregon Health & Science University, Portland, OR, USA. 11. Department of Biobehavioral Health, Pennsylvania State University, University Park, PA, USA. 12. Department of Social and Behavioral Sciences, Harvard Chan School of Public Health, Boston, MA, USA.
Abstract
The osteocyte's role in orchestrating diurnal variations in bone turnover markers (BTMs) is unclear. We identified no rhythm in serum sclerostin (osteocyte protein). These results suggest that serum sclerostin can be measured at any time of day and the osteocyte does not direct the rhythmicity of other BTMs in men. INTRODUCTION: The osteocyte exerts important effects on bone remodeling, but its rhythmicity and effect on the rhythms of other bone cells are not fully characterized. The purpose of this study was to determine if serum sclerostin displays rhythmicity over a 24-h interval, similar to that of other bone biomarkers. METHODS: Serum sclerostin, FGF-23, CTX, and P1NP were measured every 2 h over a 24-h interval in ten healthy men aged 20-65 years. Maximum likelihood estimates of the parameters in a repeated measures model were used to determine if these biomarkers displayed a diurnal, sinusoidal rhythm. RESULTS: No discernible 24-h rhythm was identified for sclerostin (p = 0.99) or P1NP (p = 0.65). CTX rhythmicity was confirmed (p < 0.001), peaking at 05:30 (range 01:30-07:30). FGF-23 levels were also rhythmic (p < 0.001), but time of peak was variable (range 02:30-11:30). The only significant association identified between these four bone biomarkers was for CTX and P1NP mean 24-h metabolite levels (r = 0.65, p = 0.04). CONCLUSIONS: Sclerostin levels do not appear to be rhythmic in men. This suggests that in contrast to CTX, serum sclerostin could be measured at any time of day. The 24-h profiles of FGF-23 suggest that a component of osteocyte function is rhythmic, but its timing is variable. Our results do not support the hypothesis that osteocytes direct the rhythmicity of other bone turnover markers (CTX), at least not via a sclerostin-mediated mechanism.
The osteocyte's role in orchestrating diurnal variations in bone turnover markers (BTMs) is unclear. We identified no rhythm in serum sclerostin (osteocyte protein). These results suggest that serum sclerostin can be measured at any time of day and the osteocyte does not direct the rhythmicity of other BTMs in men. INTRODUCTION: The osteocyte exerts important effects on bone remodeling, but its rhythmicity and effect on the rhythms of other bone cells are not fully characterized. The purpose of this study was to determine if serum sclerostin displays rhythmicity over a 24-h interval, similar to that of other bone biomarkers. METHODS: Serum sclerostin, FGF-23, CTX, and P1NP were measured every 2 h over a 24-h interval in ten healthy men aged 20-65 years. Maximum likelihood estimates of the parameters in a repeated measures model were used to determine if these biomarkers displayed a diurnal, sinusoidal rhythm. RESULTS: No discernible 24-h rhythm was identified for sclerostin (p = 0.99) or P1NP (p = 0.65). CTX rhythmicity was confirmed (p < 0.001), peaking at 05:30 (range 01:30-07:30). FGF-23 levels were also rhythmic (p < 0.001), but time of peak was variable (range 02:30-11:30). The only significant association identified between these four bone biomarkers was for CTX and P1NP mean 24-h metabolite levels (r = 0.65, p = 0.04). CONCLUSIONS:Sclerostin levels do not appear to be rhythmic in men. This suggests that in contrast to CTX, serum sclerostin could be measured at any time of day. The 24-h profiles of FGF-23 suggest that a component of osteocyte function is rhythmic, but its timing is variable. Our results do not support the hypothesis that osteocytes direct the rhythmicity of other bone turnover markers (CTX), at least not via a sclerostin-mediated mechanism.
Entities:
Keywords:
Bone remodeling; Bone turnover; Circadian rhythm; Diurnal rhythm; Osteocyte; Sclerostin
Authors: Antoon H van Lierop; Neveen At Hamdy; Herman Hamersma; Rutger L van Bezooijen; Jon Power; Nigel Loveridge; Socrates E Papapoulos Journal: J Bone Miner Res Date: 2011-12 Impact factor: 6.741
Authors: Orfeu M Buxton; Sean W Cain; Shawn P O'Connor; James H Porter; Jeanne F Duffy; Wei Wang; Charles A Czeisler; Steven A Shea Journal: Sci Transl Med Date: 2012-04-11 Impact factor: 17.956
Authors: Christine M Swanson; Steven A Shea; Pamela Wolfe; Sean W Cain; Mirjam Munch; Nina Vujovic; Charles A Czeisler; Orfeu M Buxton; Eric S Orwoll Journal: J Clin Endocrinol Metab Date: 2017-10-01 Impact factor: 5.958
Authors: Maria P Yavropoulou; Antoon H van Lierop; Neveen A T Hamdy; Rene Rizzoli; Socrates E Papapoulos Journal: Bone Date: 2012-05-02 Impact factor: 4.398
Authors: Erik Maronde; Arndt F Schilling; Sebastian Seitz; Thorsten Schinke; Isabelle Schmutz; Gijsbertus van der Horst; Michael Amling; Urs Albrecht Journal: PLoS One Date: 2010-07-12 Impact factor: 3.240
Authors: Isabelle Piec; Christopher Washbourne; Jonathan Tang; Emily Fisher; Julie Greeves; Sarah Jackson; William D Fraser Journal: Calcif Tissue Int Date: 2016-01-09 Impact factor: 4.333
Authors: Christine M Swanson; Steven A Shea; Wendy M Kohrt; Kenneth P Wright; Sean W Cain; Mirjam Munch; Nina Vujović; Charles A Czeisler; Eric S Orwoll; Orfeu M Buxton Journal: J Clin Endocrinol Metab Date: 2020-07-01 Impact factor: 5.958
Authors: Christine M Swanson; Wendy M Kohrt; Orfeu M Buxton; Carol A Everson; Kenneth P Wright; Eric S Orwoll; Steven A Shea Journal: Metabolism Date: 2017-12-09 Impact factor: 8.694
Authors: Christine M Swanson; Steven A Shea; Pamela Wolfe; Sean W Cain; Mirjam Munch; Nina Vujovic; Charles A Czeisler; Orfeu M Buxton; Eric S Orwoll Journal: J Clin Endocrinol Metab Date: 2017-10-01 Impact factor: 5.958
Authors: James C Walton; William H Walker; Jacob R Bumgarner; O Hecmarie Meléndez-Fernández; Jennifer A Liu; Heather L Hughes; Alexis L Kaper; Randy J Nelson Journal: Clin Pharmacol Ther Date: 2020-11-29 Impact factor: 6.903
Authors: Christopher M Depner; John D Rice; Emma J Tussey; Robert H Eckel; Bryan C Bergman; Janine A Higgins; Edward L Melanson; Wendy M Kohrt; Kenneth P Wright; Christine M Swanson Journal: Bone Date: 2021-06-30 Impact factor: 4.398